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N
eglected  diseases  are  ailments  that  cause 
significant morbidity or mortality but for which 
treatments are unavailable, ineffective or toxic. 
These  conditions,  which  include  HIV/AIDS,  tubercu-
losis,  malaria,  and  an  assemblage  of  “neglected  trop-
ical diseases” (NTDs) comprised of various helminthic, 
protozoan, viral and bacterial infections, primarily af-
fect  impoverished  people  in  low-  and  middle-income 
countries.1,2 The fact that most people who are affected 
by NTDs cannot afford expensive treatments has inhib-
ited investment in research and development (R&D) in 
this area. However, roughly a billion people worldwide 
are infected with one or more NTD,3 leading to 530 000 
deaths annually and a global burden of disease (GBD) of 
57 million disability adjusted life years (DALYs).4 This 
is  a  significant  GBD  when  compared  with  the  global 
burden of 84.5, 46.5 and 34.7 million DALYs attributed 
to  HIV/AIDS,  malaria  and  tuberculosis,  respectively.4 
DALYs are thought to systematically underestimate the 
burden  of  NTDs.4  The  calculation  of  DALYs  does  not 
take into account the long-term nature of NTDs or the 
subclinical morbidities associated with them.4,5 A num-
ber of studies have demonstrated that NTDs are, relative 
to their global burden, the most neglected of the world’s 
diseases.4,6 A study on the funding of ND research found 
that 30 NDs (including NTDs) received only 0.016% of 
the US$160 billion allocated to health research globally 
in 2007.6 Of the 1556 new drugs marketed between 1975 
and 2004, only 21 were indicated for neglected diseases 
(including malaria and tuberculosis, but not HIV), and a 
mere 10 were directed at NTDs.7 
Many  people  have  advocated  an  increase  in  drug 
R&D  for  NTDs,  along  with  other  medical,  social  and 
economic interventions, since effective treatments are 
predicted to have a positive impact on both the health 
status and the economic well-being of affected popula-
tions.8,9 Recently, the World Health Organization (WHO) 
Intergovernmental  Working  Group  on  Public  Health, 
Innovation  and  Intellectual  Property  has  emphasized 
the need for new R&D incentive mechanisms (e.g., prize 
funds that reward the development of innovative medic-
al interventions), intellectual property strategies such as 
patent pools, and an increase in contributions to global 
R&D from all countries, proportional to their relative 
wealth.10 In this commentary we analyze how Canada 
has responded to the NTD R&D crisis within both gov-
ernmental  and  academic  institutions.  On  the  basis  of 
this analysis, we comment on the potential for Canada 
to mitigate the suffering of the world’s poorest and most 
vulnerable people.
The role of the Canadian federal government
The  Canadian  Institutes  for  Health  Research  (CIHR) 
is Canada’s largest federal funding agency for research 
in the health sciences. In 2002, CIHR identified Global 
Health Research as one of its 5 major strategic initia-
tives11 and reaffirmed its commitment to helping Canada 
work toward the Millennium Development Goals,11 one 
of which is to address neglected diseases. We conducted 
a search to identify the proportion of publicly awarded 
research funds directed toward the 13 most prevalent 
NTDs4 (see Table 1) and found that, from 1999 to 2009, 
Canadian researchers were awarded CIHR grants and 
fellowships  in  the  amount  of  C$29.8  million  to  study 
NTDs, out of a total of C$6.36 billion (Fig. 1). The great-
est proportion of funding (C$21 million, 70%) was allo-
cated to leishmaniasis research (Fig. 2). Total research 
into NTDs represented 0.46% of the total CIHR research 
budget  from  1999  to  2009,  as  compared  with  3.99% 
for HIV, 0.22% for malaria and 0.56% for tuberculosis research during the same period. When we consider the 
global disease burden as measured by the percentage of 
total DALYs attributed to these diseases,12 the discrep-
ancy in funding becomes even more clear (Fig. 3). It is 
possible, however, that the low proportion of NTD-relat-
ed CIHR awards may reflect a lack of competitive NTD 
research  proposals,  as  opposed  to  a  bias  against  this 
type of research.
It is instructive to measure the Canadian government’s 
involvement  in  solving  the  NTD  R&D  crisis  against 
that of other countries. The first Global Funding of In-
novation  for  Neglected  Diseases  Report  (G-FINDER)6 
examined  national  contributions  to  neglected  disease 
research (including HIV/AIDS, tuberculois, malaria and 
NTDs). Canada ranked eighth in the world, contributing 
a total of US$19 million in public funding for R&D in neg-
lected diseases in 2007. These contributions were from 
CIHR, the Canadian International Development Agency, 
and the Public Health Agency of Canada, representing 
0.001% of the national GDP (Table 2). Meanwhile, the 
US  government  contributed  nearly  three-quarters  of 
global public spending with an investment of US$1.25 
billion in 2007, which corresponded to 0.009% of GDP: 
9 times the Canadian equivalent. The European Union 
accounted for US$384.9 million (0.003% GDP), primar-
ily from the United Kingdom, the Netherlands, the Re-
public of Ireland, and Sweden. At a G8 
meeting in 2008, government officials 
from the United Kingdom announced 
that they would contribute GB£50 mil-
lion  over  5  years  toward  the  control 
and elimination of NTDs, and the US 
government  pledged  US$350  million 
over  a  5-year  period  toward  global 
NTD  control  efforts.13  Unfortunately, 
Canada  has  made  no  such  commit-
ment to NTD research.
The Canadian government’s invest-
ment  in  research  for  neglected  dis-
eases generally, and NTDs specifically, 
leaves plenty of room for improvement. 
For example, the CIHR could make a 
specific  call  for  NTD  research,  offer 
NTD-specific  funding,  and  target  re-
searchers in NTDs and other biomed-
ical fields to raise awareness. Recent 
initiatives, such as the co-funding of an 
NTD Research Chair,14 should be con-
tinued  and  broadened.  Canada  could 
also contribute indirectly through ex-
ternal  NTD  R&D  initiatives,  such  as 
the not-for-profit Drugs for Neglected 
Diseases  initiative  (www.dndi.org). 
Additionally, to further support NTD 
research, we recommend that federal 
research  funding  agencies  formally 
report all basic science and drug R&D 
spending on NTDs.
We  welcome  the  recent  launch  of 
Grand Challenges Canada (GCC) (http://
www.grandchallenges.ca/),  which  has 
a mission to identify five health-related 
global grand challenges and to fund Can-
adian  and  international  researchers  to 
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Table 1: List of terms used to search the CIHR online “funding decisions” database for 
neglected tropical disease research from 1999 to 2009
Neglected tropical disease Search terms* Total funding
Leishmaniasis leishmaniasis†  8 329 697 
leishmania  20 604 805 
Human African typansomiasis human African typansomiasis  149 081 
Chagas disease Chagas disease  1 685 721 
Trachoma trachoma  3 511 227 
Leprosy leprosy  1 952 349 
Mycobacterium leprae  –   
Buruli ulcer Buruli ulcer –
Hookworm hookworm  344 300 
intestinal worms  –   
Ascariasis ascariasis  –   
Trichuriasis trichuriasis  –  
Lymphatic filariasis lymphatic filariasis  275 940 
Onchocerciasis onchocerciasis  75 530 
Guinea worm guinea worm  –  
dracunculiasis  –   
Schistosomiasis schistosoma  –   
schistosomes  –  
schistosomiasis  487 579 
swimmer’s itch _
bilharzia  –   
trematodes  –   
Total  29 086 532 
Database website: http://webapps.cihr-irsc.gc.ca/cfdd/db_search?p_language=E
* Search terms were for the 13 most prevalent neglected tropical diseases.4
† All projects found using the search term “leishmaniasis” were also found using the term “leishmania.”
Table 2: Spending on neglected disease research in relation to GDP, 2007 
Country/region
Total GDP, US$ billion 
(2007 estimates)
Spending on neglected 
disease research, 
US$billion (2007)*
% of GDP spent on  
neglected disease 
research 
United States 13 840 1.251 0.009
Canada 1 432 0.019 0.001
European Union 14 960 0.385 0.003
*As reported in Moran et al 20096address these challenges and to support implementation 
and commercialization of emergent solutions. C$225 mil-
lion over 5 years has been allocated to GCC through the 
Development Innovation Fund announced in 2008 by the 
Canadian government. While not targeted specifically at 
NTDs, this fund represents a great opportunity for NTD 
R&D. The first grand challenge announced by the GCC is 
related to the creation, development and implementation 
of new point-of-care diagnostics (http://www.grandchal-
lenges.ca/html/programs/programs.shtml). 
Beyond CIHR’s support of NTD research, the Can-
adian  government  has  an  opportunity  to  become  a 
leader in health diplomacy on the global stage. Can-
ada could begin by encouraging the formation of pat-
ent pools, or by setting up an international or Canadian 
prize fund for NTD drug development.15 Canada could 
also foster an increase in NTD drug R&D in biotech and 
biopharmaceutical  industries  by  means  of  tax  incen-
tives, regulatory exclusivity (similar to orphan drug de-
velopment in the United States16), and review vouchers 
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Figure 1: CIHR funding for research on neglected tropical diseases (NTDs), 1999–2009. Figures 
above columns show the percentage of total funding for a given year that was awarded for NTD 
research. The total funding for the 10-year period was C$6.36 billion, of which 0.46% was awarded 
for NTD research. 
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Figure 2: CIHR funding for research on neglected tropical diseases (NTDs), 1999–2009, by  
specific disease. The “other” category includes human African trypanosomiasis, lymphatic 
filariasis, schistosomaisis and hookworm. (comparable to the US FDA vouchers for NTD-targeted 
drugs17).
The role of universities
Collectively, Canadian universities account for 36% of re-
search conducted in Canada, worth an estimated C$10.4 
billion annually.18 The vision statements of these public 
institutions include performing research for the benefit 
of the public good, both locally and globally.19,20 Given 
their mandate to serve the public good, and the relative 
lack of attention to NTDs by commercial enterprise, uni-
versities are well positioned to assume an important role 
in fostering biomedical research and drug discovery for 
these diseases.21  
Universities can also help to effect change by rais-
ing  awareness  and  supporting  education  about  NTDs 
and their contribution to global health inequities. They 
can encourage new graduates to pursue NTD research 
through  postgraduate  scholarships  and  postdoctoral 
fellowships.  They  can  also  form  initiatives  that  foster 
the growth of an NTD scientific community. In line with 
this,  universities  can  coordinate  efforts  by  stakehold-
ers in NTD R&D by hosting conferences and workshops. 
To address funding challenges directly, money could be 
directed from endowment funds toward NTD drug re-
search,  or  new  endowments  could  be  established  for 
this purpose. In addition, universities can help to ensure 
equitable access to emerging treatments and technolo-
gies by strategically patenting and licensing therapeutic 
and preventive innovations in the field of NTDs.  In 2007 
the  University  of  British  Columbia  (UBC)  used  global 
access  principles  (www.uilo.ubc.ca/about/initiatives/
global.html)  when  licensing  a  new  oral  formulation  of 
amphotericin  B  (non-oral  formulations  are  associated 
with high levels of infusion-related toxicity) that has the 
potential to treat both fungal infections in HIV patients 
(which  represents  a  large  developed  world  market  for 
the formulation) and patients with leishmaniasis (occur-
ring mostly in developing countries). The presence of a 
developed  world  market  for  the  formulation  garnered 
interest from the Vancouver-based biotechnology com-
pany iCo Therapeutics to develop the product for use in 
developed countries. In an attempt to improve global ac-
cess, UBC included terms in the exclusive license with 
iCo Therapeutics to ensure at-cost prices for the formula-
tion in the developing world.22 
Within  each  of  these  efforts,  Canadian  universities 
should  partner  with  universities  in  countries  where 
NTDs  are  endemic,  through  North–South  initiatives 
for  curriculum  development,  research  collaborations, 
the creation of online communities, or direct financial 
aid for travel to conferences or research programs. It is 
encouraging  that  university-based  research  institutes 
are beginning to place greater emphasis on NTDs. For 
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Figure 3: CIHR funding for research on NTDs in comparison with proportion of global burden  
of disease, 1999–2009. The light blue columns represent the percentage of total CIHR spending 
on NTD research; the dark blue columns represent the percentage of total global DALYs accounted 
for by those same diseases (based on WHO data for 2004).12 Note that percentages shown for NTD 
DALYs are likely to be an underestimate.4,5example, at McGill University, the Institute of Parasit-
ology is conducting research on at least 4 NTDs.23 UBC 
launched a Neglected Global Diseases Initiative in Janu-
ary  2010,  which  as  a  research-based  institution  aims 
to  bring  together  multiple  disciplines  including  bench 
science,  biotechnology,  pharmaceutical  and  health  re-
search,  business,  social  policy,  and  law  to  investigate 
successful pathways of neglected disease drug develop-
ment and delivery (www.ngdi-ubc.com). In addition, a 
development of great interest at UBC is the Centre for 
Drug Research and Development (www.cdrd.ca), which 
represents a new model for preclinical drug research and 
could theoretically be harnessed in the future for NTD 
research purposes.
Conclusion
Efforts to address the NTD R&D crisis within Canada 
are occurring at the governmental as well as institution-
al level, yet are insufficient relative to the global burden 
of these infectious diseases. Although  many challenges 
are associated with fostering NTD drug R&D in high-in-
come countries, potential solutions do exist (Textbox 1). 
In addition, these proposed solutions could be extended 
to other areas of neglected disease research in general, 
such  as  malaria,  HIV/AIDS,  tuberculosis,  diarrhoeal 
illness, nutritional health, maternal health, and treat-
ment of chronic diseases in resource-poor settings. By 
uniting the efforts of government, universities, industry 
and  non-governmental  organizations,  Canada  can  act 
as a world leader in solving the NTD R&D crisis. Over 
one billion people in the world deserve a better life free 
from NTDs. As a country with the resources to respond, 
Canada has the responsibility to increase its attention 
toward the heavy burden of NTDs. Whether we will find 
the political will to do so remains to be seen. 
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